You are now leaving GSK Malta Health Portal

You are about to leave a GSK Website. By clicking this link, you will be taken to an external website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on this site. If you do not wish to leave this website, click on “Go Back” below:

Continue

Go back

MLT_GIB/OTH/0007/17m
Date of preparation: March 2018

Synflorix helps to protect against severe disease

Synflorix  is a pneumococcal conjugate vaccine which helps to protect children from 6 weeks up to 5 years of age against the bacterium Streptococcus pneumoniae1

Synflorix has also been proven to offer cross-protection against serotype 19A. Similar levels of protection against IPD caused by serotype 19A are seen with PCV13 (compared with Synflorix) 2 . In fact, results from observational studies in similar epidemiological settings do not allude to a difference between Synflorix and PCV13 on overall protection against IPD in children <2 years.3

Synflorix is the vaccine of choice for more than 50 national and regional immunisation programmes (2016). 4 To date (as of October 2017), over 500 million doses have been distributed worldwide. 5

This has meant that we have vaccinated over 140 million children globally. 4

References:

  1.  Synflorix Summary of Product Characteristics,GlaxoSmithKline. 
  2.  Deceuninck G, et al. Effectiveness of three pneumococcal conjugate vaccines to prevent invasive pneumococcal disease in Quebec, Canada. Vaccine 2015; 33(23): 2684-89
  3.  Oliveira de L.H, et al. Impact and effectiveness of PCV-10 and PCV-13 in children under 5 years in Latin America and Caribbean countries (LAC): A systematic Review. In ISPPD, June 2016.
  4.  GSK. Data on file. DGN no. 2017N343876_00
  5.  GSK. Data on file. DGN no. 2017N343614_00  

Synflorix is a trade mark of the GlaxoSmithKline group of companies.